{"gene":"TNFSF11","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1999,"finding":"OPGL/RANKL/TRANCE knockout mice completely lack osteoclasts due to inability of osteoblasts to support osteoclastogenesis, demonstrating RANKL is an essential osteoclast differentiation factor in vivo. Knockout mice also lack all lymph nodes and exhibit defects in early T and B lymphocyte differentiation, establishing roles in lymph-node organogenesis and lymphocyte development.","method":"Gene knockout mouse model (opgl-deficient mice) with skeletal, immunological, and lymph-node phenotypic analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — definitive genetic loss-of-function with multiple specific phenotypic readouts, widely replicated","pmids":["9950424"],"is_preprint":false},{"year":1999,"finding":"OPGL/RANKL directly activates mature osteoclasts by binding specifically to RANK on their surface and rapidly (within 30 min) inducing actin ring formation, a cytoskeletal rearrangement that precedes bone resorption. OPGL increases total bone surface erosion ~7-fold. Anti-RANK antibodies also induce actin ring formation, confirming RANK mediates these effects. OPG blocks both actin ring formation and bone resorption.","method":"Primary rat osteoclast cultures on bone slices, scanning electron microscopy, in vivo Ca++ measurement, antibody blocking experiments","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, receptor confirmed by antibody, replicated across labs","pmids":["10225954"],"is_preprint":false},{"year":1999,"finding":"RANKL/ODF is expressed as a membrane-associated cytokine on osteoblasts/stromal cells and signals to osteoclast precursors bearing RANK via cell-to-cell contact, inducing osteoclast differentiation in the presence of M-CSF. Membrane or matrix-associated forms of RANKL are required for osteoblast-supported osteoclastogenesis; soluble RANKL can act at a distance. Soluble OPG (decoy receptor) blocks RANKL-RANK interaction and inhibits osteoclastogenesis.","method":"Co-culture of osteoblasts/stromal cells and hematopoietic cells; spot-culture assay distinguishing membrane-bound vs. soluble forms; OPG and M-CSF neutralization","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-based reconstitution with spatial controls, multiple blocking reagents, replicated concept across labs","pmids":["10080918","10976996"],"is_preprint":false},{"year":1999,"finding":"The mouse RANKL/TNFSF11 gene promoter contains inverted TATA- and CAAT-boxes, a Cbfa1/Osf2/AML3 binding domain, and repeated half-sites for vitamin D3 and glucocorticoid receptors at -935 and -640. Short-term treatment with 1α,25(OH)2 VitD3 or dexamethasone increased promoter-driven luciferase activity ~2-fold. CpG methylation in the promoter region correlates with loss of osteoclastogenesis support capacity in stromal cells.","method":"Promoter cloning, transient transfection luciferase reporter assay, genomic Southern blot, CpG methylation analysis","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assays with multiple stimuli, single lab, no in vivo validation of specific elements","pmids":["10209265"],"is_preprint":false},{"year":2001,"finding":"TRANCE/OPGL undergoes ectodomain shedding to generate a soluble form. At least two distinct sheddase activities operate in different cell types, both distinct from TNF-alpha convertase (TACE/ADAM17). One sheddase is induced by the tyrosine phosphatase inhibitor pervanadate but not phorbol esters and is sensitive to TIMP-2 but not TIMP-1, consistent with a membrane-type matrix metalloprotease. A second sheddase is refractory to both stimuli.","method":"Biochemical characterization of cleavage site usage, pharmacological inhibition/activation with pervanadate and phorbol esters, TIMP-1 and TIMP-2 sensitivity assays in different cell types","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal pharmacological criteria in different cell lines, single lab, no direct protease identification","pmids":["11278735"],"is_preprint":false},{"year":2002,"finding":"IFN-γ produced by activated T cells inhibits RANKL-induced osteoclastogenesis by inducing rapid degradation of the RANK adapter protein TRAF6, resulting in strong inhibition of RANKL-induced NF-κB and JNK activation. Separately, RANKL induces IFN-β (but not IFN-α) gene expression in osteoclast precursor cells, and IFN-β strongly inhibits osteoclast differentiation by interfering with RANKL-induced expression of c-Fos. Both IFN-mediated mechanisms maintain bone resorption homeostasis in vivo.","method":"Genetic (IFN-KO mice, in vivo models), biochemical signaling assays (NF-κB, JNK activation), gene expression analysis, epistasis experiments","journal":"Arthritis research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic KO, signaling biochemistry, in vivo validation), two distinct IFN mechanisms characterized","pmids":["12110142"],"is_preprint":false},{"year":2003,"finding":"PTH upregulates RANKL mRNA in primary mouse bone marrow stromal osteoblasts with maximal sensitivity at late stages of osteoblast differentiation, while simultaneously inhibiting OPG gene expression at all stages. Changes in RANKL and OPG mRNA after PTH exposure are associated with increased osteoclastogenesis (increased TRACP+ cells in co-culture). PTH acts through at least protein kinase A pathway to regulate this balance.","method":"Quantitative real-time RT-PCR of RANKL and OPG mRNA at sequential differentiation stages, co-culture osteoclastogenesis assay with TRACP staining","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative gene expression plus functional co-culture readout, single lab, no direct mechanistic dissection of PTH receptor signaling to RANKL promoter","pmids":["14969393"],"is_preprint":false},{"year":2004,"finding":"RANKL acts as a survival factor in mature osteoclasts by downregulating Fas expression and Fas-mediated apoptosis. During early osteoclastogenesis, RANKL upregulates Fas promoter activity via NF-κB binding sites. In differentiated mature osteoclasts, RANKL reduces Fas expression and protects from Fas-stimulated apoptosis. The regulation of Fas by RANKL is biphasic and NF-κB-dependent.","method":"Western blotting, RT-PCR, flow cytometry, nuclear staining, caspase-3 activity assay, luciferase reporter assay, EMSA with NF-κB site mutations","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in single lab, mutagenesis of NF-κB binding sites confirms mechanism","pmids":["15619676"],"is_preprint":false},{"year":2006,"finding":"MafB negatively regulates RANKL-induced osteoclast differentiation. RANKL reduces MafB expression during osteoclastogenesis. Overexpression of MafB inhibits formation of TRAP+ multinuclear osteoclasts and attenuates RANKL-induced NFATc1 and OSCAR gene expression. MafB proteins directly interfere with the DNA-binding ability of c-Fos, Mitf, and NFATc1, inhibiting their transactivation of NFATc1 and OSCAR. RNAi knockdown of MafB enhances osteoclastogenesis.","method":"Overexpression and RNAi knockdown in bone marrow-derived monocyte/macrophage lineage cells, TRAP staining, gene expression analysis, DNA-binding interference assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both gain- and loss-of-function with mechanistic follow-up on transcription factor interference, single lab","pmids":["17158225"],"is_preprint":false},{"year":2003,"finding":"RANKL expression in skeletal tissue is regulated by a distal enhancer element (RL-D2) located 23 kb upstream of the Tnfsf11 TSS. Deletion of RL-D2 blunts PTH-induced RANKL expression in vivo and in primary stromal cells ex vivo, and leads to decreased osteoclast numbers and increased bone mineral density (high bone mass phenotype). VDR and CREB bind to this enhancer in osteoblastic cells.","method":"ChIP-seq, ChIP-chip, genomic enhancer deletion in mice (RL-D2−/− knockout), ex vivo stromal cell cultures with PTH/forskolin/1,25(OH)2D3, bone phenotype analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — enhancer deletion in vivo with in vivo and ex vivo functional validation, ChIP-seq confirmation, clear skeletal phenotype","pmids":["26332516"],"is_preprint":false},{"year":2015,"finding":"Human TNFSF11 expression in T cells is regulated by a distal enhancer region (-170 to -220 kb upstream of TSS) designated the human T cell control region (hTCCR), which is conserved with the mouse TCCR. c-FOS is recruited to the hTCCR. MEK1/2 signaling is required for RANKL induction in T cells. Enhancer segments mediate robust inducible reporter activity following TCR activation.","method":"ChIP-chip (H3/H4 acetylation), MEK1/2 inhibition with U0126, luciferase reporter assay with hTCCR segments, Jurkat cells and primary human T cells","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional reporter assays, MEK inhibition experiment, single lab","pmids":["25211367"],"is_preprint":false},{"year":2003,"finding":"Genetic rescue of RANKL-null mice using a lymphocyte-specific promoter transgene restores osteoclasts and marrow spaces in long bone diaphyses but not in periosteum or jaws, demonstrating that local delivery of RANKL is required for many site-specific skeletal processes including tooth eruption, which was not rescued. The transgene had no effect on chondrodystrophy or growth plate defects, indicating distinct tissue requirements for RANKL.","method":"Transgenic rescue of RANKL knockout mice with lymphocyte-specific promoter, histological and TRAP staining of skeletal tissues","journal":"Connective tissue research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via transgenic rescue with multiple tissue-specific readouts, single lab","pmids":["12952207"],"is_preprint":false},{"year":2008,"finding":"RANKL inhibits angiogenesis: it potently inhibits basal and VEGF-induced microvessel formation in the rat aortic ring model, inhibits endothelial cell proliferation, and induces endothelial apoptosis. Signaling studies in HUVECs showed RANKL has no effect on ERK1/2 or Akt phosphorylation (in contrast to OPG which activates these pathways), indicating RANKL's anti-angiogenic effects operate through distinct mechanisms.","method":"Rat aortic ring angiogenesis assay, HUVEC proliferation and apoptosis assays, ERK1/2 and Akt phosphorylation signaling assays","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ex vivo and cell-based assays with multiple readouts, signaling characterized, single lab","pmids":["19105036"],"is_preprint":false},{"year":2015,"finding":"FOXO1 is induced by RANKL and translocates to the nucleus in osteoclast precursors. Lineage-specific deletion of FOXO1 (LyzM.Cre+ FOXO1L/L) reduces RANKL-induced osteoclast formation and activity by ~50% in vivo and in vitro. FOXO1 mediates RANKL effects by regulating NFATc1 nuclear localization/expression and downstream osteoclast genes (DC-STAMP, ATP6vod2, cathepsin K, integrin αv). FOXO1 deletion also reduces M-CSF-induced RANK expression and osteoclast precursor migration.","method":"Conditional knockout mice (LyzM.Cre+ FOXO1L/L), siRNA knockdown in RAW264.7, in vitro osteoclastogenesis, in vivo bone phenotype, gene expression analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO plus siRNA with both in vivo and in vitro validation, single lab","pmids":["25694609"],"is_preprint":false},{"year":2014,"finding":"miR-26a is upregulated by RANKL at late stages of osteoclastogenesis. miR-26a mimic suppresses osteoclast formation, actin-ring formation, and bone resorption by targeting connective tissue growth factor/CCN2 (CTGF), which promotes osteoclast formation via DC-STAMP upregulation. Overexpression of miR-26a inhibitor enhances RANKL-induced osteoclastogenesis. Recombinant CTGF rescues the inhibitory effect of miR-26a.","method":"miRNA mimic/inhibitor transfection in osteoclast precursors, TRAP staining, actin-ring assay, bone resorption assay, gene expression analysis, rescue with recombinant CTGF","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with rescue experiment confirming CTGF as target, single lab","pmids":["25518928"],"is_preprint":false},{"year":2016,"finding":"RANKL-induced osteoclastogenesis involves an epigenetic reprogramming mechanism: RANKL induces formation of ~200 superenhancers (SEs) while suppressing ~148 SEs in human macrophages. RANKL-responsive SEs are enriched for BATF binding motifs; BATF1/3 depletion inhibits RANKL-induced osteoclast differentiation. RANKL also induces SE-associated enhancer RNAs (SE-eRNAs) at the NFATc1 locus; knockdown of SE-eRNA:NFATc1 diminishes NFATc1 expression and osteoclast differentiation. BET protein inhibition suppresses RANKL-responsive SEs and SE-eRNA:NFATc1 expression.","method":"ChIP-seq, ATAC-seq, nuclear RNA-seq, PRO-seq, BATF1/3 depletion, SE-eRNA knockdown, BET inhibitor treatment, human osteoclast differentiation assays","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal genome-wide and functional methods (ChIP-seq, ATAC-seq, KD with phenotypic rescue), single lab but highly rigorous","pmids":["36513810"],"is_preprint":false},{"year":2017,"finding":"TNFα increases RANKL expression in osteoblastic cells via PGE2-dependent activation of NFATc1 and CREB. TNFα stimulates COX2, increasing PGE2 production, which activates NFAT transcriptional activity and drives NFATc1 and CREB binding to the RANKL promoter. Mutations in the NFAT-binding element or CRE-like element in the RANKL promoter suppress TNFα/PGE2-induced RANKL promoter activity. PGE2 receptor antagonists block TNFα-induced RANKL expression.","method":"Luciferase reporter assay with RANKL promoter mutants, ChIP, NFAT inhibitors, COX inhibitor, PGE2 receptor antagonists, in C2C12 and primary calvarial cells","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis, ChIP, pharmacological inhibition with multiple agents, single lab","pmids":["28245593"],"is_preprint":false},{"year":2020,"finding":"RANKL induces beige adipocyte differentiation in preadipocytes. RANKL treatment of stromal vascular fraction (SVF) cells or 3T3-L1 preadipocytes induces multilocular morphology and increased expression of beige adipocyte marker genes. Infusion of RANKL increases respiratory rates in subcutaneous white adipose tissue and increases whole body oxygen consumption. Mature white adipocytes do not respond to RANKL-induced browning. OPG-/- mice show spontaneous sWAT browning.","method":"OPG knockout mouse model, RANKL infusion in vivo (indirect calorimetry), SVF cell differentiation assays, 3T3-L1 cell assays, histology, gene expression analysis","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo OPG-KO and RANKL infusion with in vitro cell differentiation assays, single lab","pmids":["32315212"],"is_preprint":false},{"year":2021,"finding":"RANKL-stimulated osteoclasts undergo cell fission into daughter cells called osteomorphs rather than exclusively undergoing apoptosis. Inhibiting RANKL blocked this cellular recycling and caused osteomorph accumulation. Osteomorphs are transcriptionally distinct from osteoclasts and macrophages by single-cell RNA sequencing and express non-canonical osteoclast genes associated with bone phenotypes when deleted.","method":"Intravital imaging, single-cell RNA sequencing, RANKL inhibition experiments, genetic deletion of osteomorph genes in mice","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — intravital imaging plus scRNA-seq plus genetic validation, multiple orthogonal methods in single rigorous study","pmids":["33636130"],"is_preprint":false},{"year":2021,"finding":"RANKL is highly expressed in Sertoli cells of the testis and signals through RANK expressed on germ cells, with OPG expressed in germ and peritubular cells. Mice with global or Sertoli-specific genetic suppression of Rankl have increased sperm counts and male fertility. OPG treatment increases wild-type mouse sperm counts. RANKL levels in seminal fluid are elevated and distinguish infertile from fertile men.","method":"Sertoli cell-specific and global Rankl knockout mice, OPG pharmacological treatment, seminal fluid RANKL measurement, immunohistochemistry for RANK/RANKL/OPG localization, human clinical intervention with denosumab","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional genetic KO with functional fertility readout plus pharmacological OPG treatment, single lab","pmids":["33893301"],"is_preprint":false},{"year":2021,"finding":"Under normoxia, RANKL stimulation induces ferroptosis in osteoclasts through an iron-starvation response (increased transferrin receptor 1, decreased ferritin) and activation of ferritinophagy via FTH-NCOA4 complex autophagosome degradation. This process is blocked under hypoxia, where HIF-1α inhibits autophagosome formation and autophagy flux, thereby reducing ferritinophagy. Aconitase activity reduction links RANKL stimulation to iron-starvation response.","method":"In vitro osteoclast differentiation under normoxia/hypoxia, iron homeostasis assays, autophagy flux measurement, HIF-1α inhibitor (2ME2) in vivo OVX model, FTH-NCOA4 interaction analysis","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular assays with in vivo validation, single lab, mechanism partially characterized","pmids":["33895289"],"is_preprint":false},{"year":2016,"finding":"Genetic inactivation of RANK in mammary epithelium markedly delayed onset and reduced incidence of Brca1;p53 mutation-driven mammary cancer. Long-term pharmacological RANKL inhibition abolished BRCA1 mutation-driven pre-neoplastic lesions in mice. RANK/RANKL blockade impaired proliferation and expansion of both murine Brca1;p53 mutant mammary stem cells and mammary progenitors from human BRCA1 mutation carriers.","method":"Conditional RANK knockout in mammary epithelium (two mouse models), pharmacological RANKL inhibition, mammary stem/progenitor cell proliferation assays, human BRCA1 carrier progenitor assays","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent mouse genetic models plus pharmacological blockade with human validation, multiple orthogonal methods","pmids":["27241552"],"is_preprint":false},{"year":2024,"finding":"In situ hybridization revealed that RANKL (Tnfsf11) is expressed mainly by bone surface osteoprogenitor cells (co-expressing Mmp13, Limch1, Wif1) proximate to osteoclasts, while OPG is expressed mainly by osteocytes and bone-forming osteoblasts. OPG:Fc treatment increased RANKL mRNA in trabecular bone surface cells while decreasing OPG mRNA in both bone surface cells and osteocytes. PTH treatment had a similar but more pronounced effect. These findings suggest bone surface cells and osteocytes conjointly regulate osteoclastogenesis activation.","method":"In situ hybridization across multiple species and skeletal sites, OPG:Fc and PTH treatment of mice, scRNA-seq analysis of murine bone marrow stromal cells","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ISH localization with functional pharmacological interventions in vivo, supported by scRNA-seq, single lab","pmids":["39424806"],"is_preprint":false},{"year":2021,"finding":"RANKL and RANK are present as functional components in extracellular vesicles (EVs). RANK in EVs from osteoclasts can stimulate a RANKL reverse signaling pathway in osteoblasts that promotes bone formation, serving to couple bone resorption with bone formation.","method":"Extracellular vesicle isolation, functional assays of RANK-containing EVs on osteoblast bone formation","journal":"Extracellular vesicles and circulating nucleic acids","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review article summarizing EV findings; limited primary experimental detail available in this abstract","pmids":["33982033"],"is_preprint":false}],"current_model":"RANKL (TNFSF11) is a TNF-family membrane-bound and soluble cytokine expressed by osteoblasts, osteocytes, and other cells that acts as the essential ligand for the receptor RANK on osteoclast precursors and mature osteoclasts, driving osteoclast differentiation, activation (actin ring formation), and survival by suppressing Fas-mediated apoptosis via NF-κB, while its activity is antagonized by the soluble decoy receptor OPG; RANKL expression is transcriptionally controlled by distal genomic enhancers (RL-D2, RL-D5, hTCCR) responsive to PTH, 1,25(OH)2D3, and TCR activation via VDR, CREB, c-Fos, and NFATc1 binding, and is epigenetically reprogrammed during osteoclastogenesis through superenhancer remodeling involving BATF and SE-eRNAs; RANKL also regulates lymph-node organogenesis, lymphocyte development, mammary gland lactational development, thermoregulation via CNS COX2-PGE2/EP3R signaling, male fertility via Sertoli cell-germ cell RANK signaling, beige adipocyte differentiation, and BRCA1-driven mammary tumorigenesis by controlling progenitor cell expansion, and undergoes ectodomain shedding by at least two distinct metalloprotease activities to generate its soluble form."},"narrative":{"mechanistic_narrative":"TNFSF11 (RANKL) is the essential, membrane-bound and soluble TNF-family cytokine that licenses osteoclast formation and broader developmental programs, established genetically by the complete absence of osteoclasts, lymph nodes, and normal lymphocyte differentiation in knockout mice [PMID:9950424]. Expressed as a membrane-associated cytokine on osteoblasts and stromal cells, RANKL signals through cell-to-cell contact to RANK on hematopoietic osteoclast precursors, driving their differentiation in the presence of M-CSF; soluble RANKL generated by ectodomain shedding can act at a distance, and the decoy receptor OPG blocks the RANKL-RANK interaction [PMID:10080918, PMID:10976996, PMID:11278735]. In situ analysis localizes RANKL to bone-surface osteoprogenitor cells adjacent to osteoclasts while OPG is enriched in osteocytes and bone-forming osteoblasts, defining a spatially partitioned regulatory circuit [PMID:39424806]. Beyond differentiation, RANKL directly activates mature osteoclasts—rapidly inducing actin-ring formation and bone-surface erosion through RANK [PMID:10225954]—and acts as a survival factor by suppressing Fas-mediated apoptosis in an NF-κB-dependent, biphasic manner [PMID:15619676]. Downstream of RANK, RANKL drives a transcriptional cascade centered on NFATc1 and c-Fos, modulated positively by FOXO1 [PMID:25694609] and restrained by MafB, which interferes with c-Fos, Mitf, and NFATc1 DNA binding [PMID:17158225]; this program is amplified through epigenetic reprogramming, with RANKL inducing BATF-dependent superenhancers and an SE-eRNA at the NFATc1 locus [PMID:36513810]. RANKL transcription itself is controlled by distal enhancers responsive to PTH and 1,25(OH)2D3 via VDR and CREB in osteoblasts (RL-D2) [PMID:26332516] and to TCR/MEK signaling via c-FOS in T cells (hTCCR) [PMID:25211367], and by TNFα through PGE2-driven NFATc1/CREB binding to the promoter [PMID:28245593]. Osteoclastogenesis is counter-regulated by IFN-β (which suppresses c-Fos) and by T-cell-derived IFN-γ (which degrades TRAF6) [PMID:12110142]. RANKL also operates well beyond bone, governing beige adipocyte differentiation and thermogenesis [PMID:32315212], Sertoli-cell-to-germ-cell signaling that restrains male fertility [PMID:33893301], and BRCA1/p53-driven mammary tumorigenesis through expansion of mammary stem and progenitor cells [PMID:27241552].","teleology":[{"year":1999,"claim":"Establishing whether RANKL is genuinely required for osteoclast formation in vivo answered whether bone resorption depends on a single dedicated ligand and revealed its developmental breadth.","evidence":"Gene knockout mouse with skeletal, immunological, and lymph-node phenotyping","pmids":["9950424"],"confidence":"High","gaps":["Does not resolve the receptor or signaling mechanism","Does not distinguish membrane-bound versus soluble ligand requirements"]},{"year":1999,"claim":"Defining how RANKL is presented to precursors and how it engages mature cells answered whether it acts via contact-dependent membrane signaling and direct activation through RANK.","evidence":"Osteoblast/precursor co-culture, spot-culture distinguishing membrane vs soluble forms, primary osteoclast bone-slice assays with anti-RANK and OPG blockade","pmids":["10080918","10976996","10225954"],"confidence":"High","gaps":["Does not identify the intracellular signaling adapters","Does not define the sheddase generating soluble RANKL"]},{"year":2001,"claim":"Characterizing ectodomain shedding answered how the soluble RANKL form is produced, revealing at least two distinct metalloprotease activities separable from TACE/ADAM17.","evidence":"Pharmacological shedding assays with pervanadate/phorbol esters and TIMP-1/TIMP-2 sensitivity across cell types","pmids":["11278735"],"confidence":"Medium","gaps":["No protease molecularly identified","Physiological contribution of soluble vs membrane RANKL in vivo unresolved"]},{"year":2002,"claim":"Mapping immune counter-regulation answered how T-cell signals brake osteoclastogenesis, identifying TRAF6 degradation by IFN-γ and c-Fos suppression by RANKL-induced IFN-β.","evidence":"IFN-knockout mice, NF-κB/JNK signaling biochemistry, gene expression and epistasis","pmids":["12110142"],"confidence":"High","gaps":["Does not quantify relative contribution of the two IFN arms in disease","Mechanism of RANKL-induced IFN-β induction not fully dissected"]},{"year":2003,"claim":"Dissecting promoter and rescue requirements answered how RANKL transcription responds to vitamin D/glucocorticoids and whether local versus systemic delivery dictates site-specific skeletal function.","evidence":"Promoter luciferase reporters with CpG methylation analysis; lymphocyte-promoter transgenic rescue of RANKL-null mice","pmids":["10209265","12952207"],"confidence":"Medium","gaps":["Promoter elements not validated in vivo at endogenous locus","Does not explain tooth-eruption and growth-plate non-rescue mechanistically"]},{"year":2004,"claim":"Resolving the survival role answered whether RANKL controls osteoclast lifespan, showing biphasic NF-κB-dependent regulation of Fas.","evidence":"Reporter assays, EMSA with NF-κB site mutants, caspase-3 and apoptosis assays in osteoclasts","pmids":["15619676"],"confidence":"Medium","gaps":["Switch governing the early-up/late-down biphasic response not defined","In vivo relevance to bone turnover not established here"]},{"year":2006,"claim":"Identifying MafB answered how the osteoclast transcriptional program is restrained, placing a brake on c-Fos/Mitf/NFATc1 DNA binding downstream of RANKL.","evidence":"Overexpression/RNAi in monocyte lineage cells, TRAP staining, DNA-binding interference assays","pmids":["17158225"],"confidence":"Medium","gaps":["Upstream control of MafB downregulation by RANKL unresolved","Structural basis of transcription-factor interference not defined"]},{"year":2008,"claim":"Testing vascular effects answered whether RANKL acts on endothelium, showing it inhibits angiogenesis through mechanisms distinct from OPG-driven ERK/Akt activation.","evidence":"Rat aortic ring assay, HUVEC proliferation/apoptosis, ERK1/2 and Akt phosphorylation assays","pmids":["19105036"],"confidence":"Medium","gaps":["Receptor and signaling pathway mediating anti-angiogenic effect unidentified","In vivo angiogenesis relevance not established"]},{"year":2014,"claim":"Adding a microRNA layer answered how RANKL fine-tunes late osteoclastogenesis, with miR-26a targeting CTGF to limit DC-STAMP-driven fusion.","evidence":"miRNA mimic/inhibitor transfection, TRAP/actin-ring/resorption assays, recombinant CTGF rescue","pmids":["25518928"],"confidence":"Medium","gaps":["In vivo skeletal role of the miR-26a/CTGF axis untested","How RANKL induces miR-26a not defined"]},{"year":2015,"claim":"Mapping enhancers in osteoblasts and T cells answered how RANKL transcription is wired to hormonal and immune cues, defining RL-D2 (VDR/CREB, PTH-responsive) and the hTCCR (c-FOS, MEK/TCR-responsive), and FOXO1 as an intracellular RANKL effector.","evidence":"ChIP-seq/ChIP-chip, in vivo enhancer deletion (RL-D2−/−), hTCCR reporter and MEK inhibition; FOXO1 conditional KO and siRNA with osteoclast assays","pmids":["26332516","25211367","25694609"],"confidence":"High","gaps":["Crosstalk between osteoblast and T-cell enhancers not addressed","FOXO1 mechanism of NFATc1 regulation only partly defined"]},{"year":2016,"claim":"Genome-wide epigenetic profiling answered how RANKL reprograms the osteoclast genome, identifying BATF-dependent superenhancers and an NFATc1 SE-eRNA as essential drivers.","evidence":"ChIP-seq, ATAC-seq, PRO-seq, BATF1/3 depletion, SE-eRNA knockdown, BET inhibition in human osteoclasts","pmids":["36513810"],"confidence":"High","gaps":["Signaling linking RANK to BATF recruitment unresolved","Mechanism of SE-eRNA action on NFATc1 not defined"]},{"year":2016,"claim":"Probing the mammary axis answered whether RANK/RANKL drives BRCA1-mutant tumorigenesis, showing it expands cancer-prone stem and progenitor cells.","evidence":"Conditional mammary RANK KO (two models), pharmacological RANKL inhibition, murine and human BRCA1-carrier progenitor assays","pmids":["27241552"],"confidence":"High","gaps":["Downstream effectors of RANK in progenitor expansion not identified","Does not establish RANKL source within the mammary niche"]},{"year":2020,"claim":"Testing adipose effects answered whether RANKL influences metabolism, showing it drives beige adipocyte differentiation and thermogenesis in precursors but not mature white adipocytes.","evidence":"OPG-KO mice, in vivo RANKL infusion with indirect calorimetry, SVF and 3T3-L1 differentiation assays","pmids":["32315212"],"confidence":"Medium","gaps":["Receptor/signaling pathway in preadipocytes not defined","Whether RANKL acts cell-autonomously on precursors unresolved"]},{"year":2021,"claim":"Imaging osteoclast fate answered whether resorbing cells simply die, revealing RANKL-dependent fission into transcriptionally distinct osteomorphs that recycle.","evidence":"Intravital imaging, single-cell RNA-seq, RANKL inhibition, genetic deletion of osteomorph genes","pmids":["33636130"],"confidence":"High","gaps":["Molecular trigger of fission versus apoptosis not defined","Functional contribution of osteomorph recycling to bone homeostasis incompletely quantified"]},{"year":2021,"claim":"Examining testis and cell-death pathways answered additional non-skeletal and metabolic roles: Sertoli-cell RANKL restrains male fertility via germ-cell RANK, and RANKL induces ferroptosis through ferritinophagy in normoxic osteoclasts.","evidence":"Sertoli-specific/global Rankl KO, OPG and denosumab treatment, seminal RANKL measurement; iron-homeostasis and autophagy-flux assays with HIF-1α inhibition in OVX model","pmids":["33893301","33895289"],"confidence":"Medium","gaps":["Germ-cell signaling downstream of RANK in fertility not mapped","In vivo significance of RANKL-induced ferroptosis under physiological oxygen tension unresolved"]},{"year":2021,"claim":"Proposing EV-borne reverse signaling addressed how resorption couples to formation, suggesting osteoclast EV RANK triggers RANKL reverse signaling in osteoblasts.","evidence":"EV isolation and functional assays on osteoblast bone formation (review summary)","pmids":["33982033"],"confidence":"Low","gaps":["Review-level summary lacking primary mechanistic detail","RANKL reverse-signaling pathway in osteoblasts not molecularly defined","In vivo contribution to coupling unestablished"]},{"year":2024,"claim":"Spatial localization answered which cells supply RANKL versus OPG, defining a division of labor between bone-surface osteoprogenitors and osteocytes in regulating osteoclastogenesis.","evidence":"In situ hybridization across species/sites, OPG:Fc and PTH treatment, scRNA-seq of bone marrow stroma","pmids":["39424806"],"confidence":"Medium","gaps":["Mechanism coordinating the two cell populations not defined","Does not establish causal contribution of each source in vivo"]},{"year":null,"claim":"The molecular identity of the RANKL sheddases, the receptor mediating its non-skeletal effects (angiogenesis, adipose browning), and the molecular basis of RANKL reverse signaling remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["Sheddase enzymes not molecularly identified","Receptor for anti-angiogenic and beige-adipocyte effects unknown","Reverse-signaling pathway in osteoblasts uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,4]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,2]}],"pathway":[],"complexes":[],"partners":["TNFRSF11A","TNFRSF11B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14788","full_name":"Tumor necrosis factor ligand superfamily member 11","aliases":["Osteoclast differentiation factor","ODF","Osteoprotegerin ligand","OPGL","Receptor activator of nuclear factor kappa-B ligand","RANKL","TNF-related activation-induced cytokine","TRANCE"],"length_aa":317,"mass_kda":35.5,"function":"Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O14788/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF11","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF11","total_profiled":1310},"omim":[{"mim_id":"619820","title":"ATONAL bHLH TRANSCRIPTION FACTOR 8; ATOH8","url":"https://www.omim.org/entry/619820"},{"mim_id":"618749","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 17; LRRC17","url":"https://www.omim.org/entry/618749"},{"mim_id":"618107","title":"OSTEOPETROSIS, AUTOSOMAL DOMINANT 3; OPTA3","url":"https://www.omim.org/entry/618107"},{"mim_id":"617165","title":"PEROXIREDOXIN-LIKE 2A; PRXL2A","url":"https://www.omim.org/entry/617165"},{"mim_id":"616967","title":"THIOREDOXIN DOMAIN-CONTAINING PROTEIN 17; TXNDC17","url":"https://www.omim.org/entry/616967"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":3.9},{"tissue":"lymphoid tissue","ntpm":11.5}],"url":"https://www.proteinatlas.org/search/TNFSF11"},"hgnc":{"alias_symbol":["TRANCE","RANKL","OPGL","ODF","CD254"],"prev_symbol":[]},"alphafold":{"accession":"O14788","domains":[{"cath_id":"2.60.120.40","chopping":"166-316","consensus_level":"high","plddt":96.6026,"start":166,"end":316},{"cath_id":"1.20.5","chopping":"115-144","consensus_level":"high","plddt":71.7643,"start":115,"end":144}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14788","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14788-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14788-F1-predicted_aligned_error_v6.png","plddt_mean":79.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF11","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF11"},"sequence":{"accession":"O14788","fasta_url":"https://rest.uniprot.org/uniprotkb/O14788.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14788/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14788"}},"corpus_meta":[{"pmid":"9950424","id":"PMC_9950424","title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9950424","citation_count":2616,"is_preprint":false},{"pmid":"11713196","id":"PMC_11713196","title":"Minireview: the OPG/RANKL/RANK system.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11713196","citation_count":1050,"is_preprint":false},{"pmid":"16356770","id":"PMC_16356770","title":"RANKL-RANK signaling in osteoclastogenesis and bone disease.","date":"2005","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16356770","citation_count":935,"is_preprint":false},{"pmid":"17634140","id":"PMC_17634140","title":"Biology of RANK, RANKL, and osteoprotegerin.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634140","citation_count":696,"is_preprint":false},{"pmid":"33079279","id":"PMC_33079279","title":"Osteoclast differentiation by RANKL and OPG signaling pathways.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33079279","citation_count":536,"is_preprint":false},{"pmid":"10225954","id":"PMC_10225954","title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10225954","citation_count":534,"is_preprint":false},{"pmid":"10080918","id":"PMC_10080918","title":"A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10080918","citation_count":366,"is_preprint":false},{"pmid":"33636130","id":"PMC_33636130","title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33636130","citation_count":297,"is_preprint":false},{"pmid":"22092994","id":"PMC_22092994","title":"The RANKL-OPG system in clinical periodontology.","date":"2011","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/22092994","citation_count":266,"is_preprint":false},{"pmid":"14969393","id":"PMC_14969393","title":"PTH differentially regulates expression of RANKL and OPG.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/14969393","citation_count":264,"is_preprint":false},{"pmid":"17925190","id":"PMC_17925190","title":"The RANKL/RANK/OPG pathway.","date":"2007","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/17925190","citation_count":259,"is_preprint":false},{"pmid":"16313339","id":"PMC_16313339","title":"Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16313339","citation_count":256,"is_preprint":false},{"pmid":"17158225","id":"PMC_17158225","title":"MafB negatively regulates RANKL-mediated osteoclast differentiation.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17158225","citation_count":221,"is_preprint":false},{"pmid":"16188502","id":"PMC_16188502","title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.","date":"2005","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16188502","citation_count":214,"is_preprint":false},{"pmid":"19419454","id":"PMC_19419454","title":"RANK/RANKL/OPG during orthodontic tooth movement.","date":"2009","source":"Orthodontics & craniofacial research","url":"https://pubmed.ncbi.nlm.nih.gov/19419454","citation_count":201,"is_preprint":false},{"pmid":"16313338","id":"PMC_16313338","title":"Osteoclast precursors, RANKL/RANK, and immunology.","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16313338","citation_count":187,"is_preprint":false},{"pmid":"15615494","id":"PMC_15615494","title":"The OPG/RANKL/RANK system in metabolic bone diseases.","date":"2004","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/15615494","citation_count":183,"is_preprint":false},{"pmid":"21618594","id":"PMC_21618594","title":"Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21618594","citation_count":183,"is_preprint":false},{"pmid":"33389131","id":"PMC_33389131","title":"Discovery of the RANKL/RANK/OPG system.","date":"2021","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33389131","citation_count":169,"is_preprint":false},{"pmid":"10380891","id":"PMC_10380891","title":"TRANCE is a TNF family member that regulates dendritic cell and osteoclast function.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10380891","citation_count":166,"is_preprint":false},{"pmid":"12379618","id":"PMC_12379618","title":"Role of RANKL and RANK in bone loss and arthritis.","date":"2002","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/12379618","citation_count":162,"is_preprint":false},{"pmid":"25557611","id":"PMC_25557611","title":"RANKL/OPG; Critical role in bone physiology.","date":"2015","source":"Reviews in endocrine & metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/25557611","citation_count":161,"is_preprint":false},{"pmid":"33895289","id":"PMC_33895289","title":"Hypoxia inhibits RANKL-induced ferritinophagy and protects osteoclasts from ferroptosis.","date":"2021","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33895289","citation_count":152,"is_preprint":false},{"pmid":"22113597","id":"PMC_22113597","title":"Rank/Rankl/opg: literature review.","date":"2011","source":"Acta reumatologica portuguesa","url":"https://pubmed.ncbi.nlm.nih.gov/22113597","citation_count":142,"is_preprint":false},{"pmid":"25720990","id":"PMC_25720990","title":"The RANKL-RANK Story.","date":"2015","source":"Gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/25720990","citation_count":139,"is_preprint":false},{"pmid":"27241552","id":"PMC_27241552","title":"RANKL/RANK control Brca1 mutation- .","date":"2016","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27241552","citation_count":139,"is_preprint":false},{"pmid":"27279652","id":"PMC_27279652","title":"RANK-RANKL signalling in cancer.","date":"2016","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/27279652","citation_count":134,"is_preprint":false},{"pmid":"19191757","id":"PMC_19191757","title":"Action of RANKL and OPG for osteoclastogenesis.","date":"2009","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/19191757","citation_count":133,"is_preprint":false},{"pmid":"11521937","id":"PMC_11521937","title":"The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.","date":"2001","source":"The Journal of bone and joint surgery. British volume","url":"https://pubmed.ncbi.nlm.nih.gov/11521937","citation_count":130,"is_preprint":false},{"pmid":"12110142","id":"PMC_12110142","title":"Signaling crosstalk between RANKL and interferons in osteoclast differentiation.","date":"2002","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/12110142","citation_count":127,"is_preprint":false},{"pmid":"17530461","id":"PMC_17530461","title":"RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.","date":"2007","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/17530461","citation_count":125,"is_preprint":false},{"pmid":"20571772","id":"PMC_20571772","title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","date":"2010","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/20571772","citation_count":125,"is_preprint":false},{"pmid":"10209265","id":"PMC_10209265","title":"Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10209265","citation_count":119,"is_preprint":false},{"pmid":"21445556","id":"PMC_21445556","title":"RANKL/RANK-beyond bones.","date":"2011","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/21445556","citation_count":112,"is_preprint":false},{"pmid":"11278735","id":"PMC_11278735","title":"Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278735","citation_count":107,"is_preprint":false},{"pmid":"21196156","id":"PMC_21196156","title":"Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196156","citation_count":105,"is_preprint":false},{"pmid":"17634146","id":"PMC_17634146","title":"Clinical development of anti-RANKL therapy.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634146","citation_count":102,"is_preprint":false},{"pmid":"35181574","id":"PMC_35181574","title":"RANKL biology.","date":"2022","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/35181574","citation_count":96,"is_preprint":false},{"pmid":"33070252","id":"PMC_33070252","title":"RANKL and osteoimmunology in periodontitis.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33070252","citation_count":90,"is_preprint":false},{"pmid":"19239825","id":"PMC_19239825","title":"Denosumab: anti-RANKL antibody.","date":"2009","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/19239825","citation_count":89,"is_preprint":false},{"pmid":"35902802","id":"PMC_35902802","title":"Artemisinin relieves osteoarthritis by activating mitochondrial autophagy through reducing TNFSF11 expression and inhibiting PI3K/AKT/mTOR signaling in cartilage.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35902802","citation_count":87,"is_preprint":false},{"pmid":"27456834","id":"PMC_27456834","title":"Proinflammatory M1 Macrophages Inhibit RANKL-Induced Osteoclastogenesis.","date":"2016","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27456834","citation_count":86,"is_preprint":false},{"pmid":"24929185","id":"PMC_24929185","title":"The immune system, bone and RANKL.","date":"2014","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/24929185","citation_count":79,"is_preprint":false},{"pmid":"29241686","id":"PMC_29241686","title":"RANKL and RANK: From Mammalian Physiology to Cancer Treatment.","date":"2017","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29241686","citation_count":76,"is_preprint":false},{"pmid":"24432249","id":"PMC_24432249","title":"Effects of RANKL-Targeted Therapy in Immunity and Cancer.","date":"2014","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24432249","citation_count":76,"is_preprint":false},{"pmid":"12548579","id":"PMC_12548579","title":"RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.","date":"2003","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12548579","citation_count":74,"is_preprint":false},{"pmid":"26659571","id":"PMC_26659571","title":"RANKL blockade prevents and treats aggressive osteosarcomas.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26659571","citation_count":74,"is_preprint":false},{"pmid":"30929797","id":"PMC_30929797","title":"RANKL-independent modulation of osteoclastogenesis.","date":"2019","source":"Journal of oral biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30929797","citation_count":73,"is_preprint":false},{"pmid":"19105036","id":"PMC_19105036","title":"Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.","date":"2008","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19105036","citation_count":72,"is_preprint":false},{"pmid":"20163972","id":"PMC_20163972","title":"RANK/RANKL/OPG role in distraction osteogenesis.","date":"2010","source":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/20163972","citation_count":72,"is_preprint":false},{"pmid":"12707582","id":"PMC_12707582","title":"RANKL and RANK as novel therapeutic targets for arthritis.","date":"2003","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12707582","citation_count":71,"is_preprint":false},{"pmid":"36513810","id":"PMC_36513810","title":"RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts.","date":"2022","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36513810","citation_count":66,"is_preprint":false},{"pmid":"15785827","id":"PMC_15785827","title":"RANK, RANKL and osteoprotegerin in arthritic bone loss.","date":"2005","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/15785827","citation_count":64,"is_preprint":false},{"pmid":"25518928","id":"PMC_25518928","title":"MicroRNA-26a regulates RANKL-induced osteoclast formation.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25518928","citation_count":64,"is_preprint":false},{"pmid":"10976996","id":"PMC_10976996","title":"Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.","date":"2000","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/10976996","citation_count":63,"is_preprint":false},{"pmid":"24719884","id":"PMC_24719884","title":"RANKL expression in periodontal disease: where does RANKL come from?","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24719884","citation_count":62,"is_preprint":false},{"pmid":"27871200","id":"PMC_27871200","title":"Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.","date":"2016","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27871200","citation_count":60,"is_preprint":false},{"pmid":"24795813","id":"PMC_24795813","title":"Targeting RANKL in metastasis.","date":"2014","source":"BoneKEy reports","url":"https://pubmed.ncbi.nlm.nih.gov/24795813","citation_count":58,"is_preprint":false},{"pmid":"32850393","id":"PMC_32850393","title":"Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32850393","citation_count":58,"is_preprint":false},{"pmid":"17634142","id":"PMC_17634142","title":"Role of RANKL inhibition in osteoporosis.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634142","citation_count":57,"is_preprint":false},{"pmid":"21850548","id":"PMC_21850548","title":"Relationship between serum RANKL and RANKL in bone.","date":"2011","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/21850548","citation_count":56,"is_preprint":false},{"pmid":"24477414","id":"PMC_24477414","title":"Regulatory mechanisms of RANKL presentation to osteoclast precursors.","date":"2014","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/24477414","citation_count":54,"is_preprint":false},{"pmid":"15619676","id":"PMC_15619676","title":"RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.","date":"2004","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/15619676","citation_count":54,"is_preprint":false},{"pmid":"33057808","id":"PMC_33057808","title":"RANKL as a target for the treatment of osteoporosis.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33057808","citation_count":53,"is_preprint":false},{"pmid":"12952207","id":"PMC_12952207","title":"The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue.","date":"2003","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/12952207","citation_count":53,"is_preprint":false},{"pmid":"16479591","id":"PMC_16479591","title":"Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16479591","citation_count":52,"is_preprint":false},{"pmid":"24486161","id":"PMC_24486161","title":"RANKL/RANK - from bone physiology to breast cancer.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24486161","citation_count":50,"is_preprint":false},{"pmid":"23665018","id":"PMC_23665018","title":"AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23665018","citation_count":50,"is_preprint":false},{"pmid":"34440747","id":"PMC_34440747","title":"The Roadmap of RANKL/RANK Pathway in Cancer.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34440747","citation_count":49,"is_preprint":false},{"pmid":"30984193","id":"PMC_30984193","title":"The RANKL-RANK Axis: A Bone to Thymus Round Trip.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30984193","citation_count":49,"is_preprint":false},{"pmid":"39424806","id":"PMC_39424806","title":"Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.","date":"2024","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/39424806","citation_count":48,"is_preprint":false},{"pmid":"29499125","id":"PMC_29499125","title":"RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis.","date":"2018","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/29499125","citation_count":45,"is_preprint":false},{"pmid":"30609798","id":"PMC_30609798","title":"(-)-Epigallocatechin-3-Gallate Decreases Osteoclastogenesis via Modulation of RANKL and Osteoprotegrin.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30609798","citation_count":43,"is_preprint":false},{"pmid":"33893301","id":"PMC_33893301","title":"RANKL regulates male reproductive function.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33893301","citation_count":41,"is_preprint":false},{"pmid":"21259010","id":"PMC_21259010","title":"The expression of RANKL and OPG in the various grades of osteoarthritic cartilage.","date":"2011","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/21259010","citation_count":41,"is_preprint":false},{"pmid":"14675140","id":"PMC_14675140","title":"Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.","date":"2004","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14675140","citation_count":39,"is_preprint":false},{"pmid":"29717113","id":"PMC_29717113","title":"CCL4 enhances preosteoclast migration and its receptor CCR5 downregulation by RANKL promotes osteoclastogenesis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29717113","citation_count":39,"is_preprint":false},{"pmid":"33070253","id":"PMC_33070253","title":"RANKL as a therapeutic target of rheumatoid arthritis.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33070253","citation_count":38,"is_preprint":false},{"pmid":"27403809","id":"PMC_27403809","title":"Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27403809","citation_count":36,"is_preprint":false},{"pmid":"11137033","id":"PMC_11137033","title":"Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone.","date":"2001","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/11137033","citation_count":36,"is_preprint":false},{"pmid":"33982033","id":"PMC_33982033","title":"RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling.","date":"2021","source":"Extracellular vesicles and circulating nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33982033","citation_count":36,"is_preprint":false},{"pmid":"15615495","id":"PMC_15615495","title":"RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.","date":"2004","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/15615495","citation_count":34,"is_preprint":false},{"pmid":"33994070","id":"PMC_33994070","title":"The hidden secrets of soluble RANKL in bone biology.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/33994070","citation_count":34,"is_preprint":false},{"pmid":"21087090","id":"PMC_21087090","title":"Physiology and pathophysiology of the RANKL/RANK system.","date":"2010","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21087090","citation_count":34,"is_preprint":false},{"pmid":"21327765","id":"PMC_21327765","title":"Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.","date":"2011","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/21327765","citation_count":32,"is_preprint":false},{"pmid":"25694609","id":"PMC_25694609","title":"FOXO1 mediates RANKL-induced osteoclast formation and activity.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25694609","citation_count":31,"is_preprint":false},{"pmid":"23392729","id":"PMC_23392729","title":"Endotoxins potentiate COX-2 and RANKL expression in compressed PDL cells.","date":"2013","source":"Clinical oral investigations","url":"https://pubmed.ncbi.nlm.nih.gov/23392729","citation_count":30,"is_preprint":false},{"pmid":"22023901","id":"PMC_22023901","title":"The RANKL pathway and denosumab.","date":"2011","source":"Rheumatic diseases clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/22023901","citation_count":29,"is_preprint":false},{"pmid":"25211367","id":"PMC_25211367","title":"Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25211367","citation_count":29,"is_preprint":false},{"pmid":"29259683","id":"PMC_29259683","title":"RANKL system in vascular and valve calcification with aging.","date":"2016","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29259683","citation_count":29,"is_preprint":false},{"pmid":"27783278","id":"PMC_27783278","title":"Can we prevent BRCA1-associated breast cancer by RANKL inhibition?","date":"2016","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/27783278","citation_count":28,"is_preprint":false},{"pmid":"32971123","id":"PMC_32971123","title":"Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.","date":"2020","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/32971123","citation_count":28,"is_preprint":false},{"pmid":"26332516","id":"PMC_26332516","title":"Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26332516","citation_count":28,"is_preprint":false},{"pmid":"28733136","id":"PMC_28733136","title":"Unexpected Bone Formation Produced by RANKL Blockade.","date":"2017","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/28733136","citation_count":27,"is_preprint":false},{"pmid":"16730419","id":"PMC_16730419","title":"Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women.","date":"2006","source":"Maturitas","url":"https://pubmed.ncbi.nlm.nih.gov/16730419","citation_count":27,"is_preprint":false},{"pmid":"20531232","id":"PMC_20531232","title":"TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women.","date":"2010","source":"Menopause (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20531232","citation_count":25,"is_preprint":false},{"pmid":"28576140","id":"PMC_28576140","title":"RANK/RANKL/OPG system in the intervertebral disc.","date":"2017","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28576140","citation_count":24,"is_preprint":false},{"pmid":"32315212","id":"PMC_32315212","title":"RANKL induces beige adipocyte differentiation in preadipocytes.","date":"2020","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32315212","citation_count":24,"is_preprint":false},{"pmid":"33633362","id":"PMC_33633362","title":"RANKL/OPG ratio regulates odontoclastogenesis in damaged dental pulp.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33633362","citation_count":24,"is_preprint":false},{"pmid":"28245593","id":"PMC_28245593","title":"TNFα Increases RANKL Expression via PGE₂-Induced Activation of NFATc1.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28245593","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46348,"output_tokens":7022,"usd":0.122187,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16267,"output_tokens":5353,"usd":0.10758,"stage2_stop_reason":"end_turn"},"total_usd":0.229767,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"OPGL/RANKL/TRANCE knockout mice completely lack osteoclasts due to inability of osteoblasts to support osteoclastogenesis, demonstrating RANKL is an essential osteoclast differentiation factor in vivo. Knockout mice also lack all lymph nodes and exhibit defects in early T and B lymphocyte differentiation, establishing roles in lymph-node organogenesis and lymphocyte development.\",\n      \"method\": \"Gene knockout mouse model (opgl-deficient mice) with skeletal, immunological, and lymph-node phenotypic analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — definitive genetic loss-of-function with multiple specific phenotypic readouts, widely replicated\",\n      \"pmids\": [\"9950424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"OPGL/RANKL directly activates mature osteoclasts by binding specifically to RANK on their surface and rapidly (within 30 min) inducing actin ring formation, a cytoskeletal rearrangement that precedes bone resorption. OPGL increases total bone surface erosion ~7-fold. Anti-RANK antibodies also induce actin ring formation, confirming RANK mediates these effects. OPG blocks both actin ring formation and bone resorption.\",\n      \"method\": \"Primary rat osteoclast cultures on bone slices, scanning electron microscopy, in vivo Ca++ measurement, antibody blocking experiments\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, receptor confirmed by antibody, replicated across labs\",\n      \"pmids\": [\"10225954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RANKL/ODF is expressed as a membrane-associated cytokine on osteoblasts/stromal cells and signals to osteoclast precursors bearing RANK via cell-to-cell contact, inducing osteoclast differentiation in the presence of M-CSF. Membrane or matrix-associated forms of RANKL are required for osteoblast-supported osteoclastogenesis; soluble RANKL can act at a distance. Soluble OPG (decoy receptor) blocks RANKL-RANK interaction and inhibits osteoclastogenesis.\",\n      \"method\": \"Co-culture of osteoblasts/stromal cells and hematopoietic cells; spot-culture assay distinguishing membrane-bound vs. soluble forms; OPG and M-CSF neutralization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-based reconstitution with spatial controls, multiple blocking reagents, replicated concept across labs\",\n      \"pmids\": [\"10080918\", \"10976996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The mouse RANKL/TNFSF11 gene promoter contains inverted TATA- and CAAT-boxes, a Cbfa1/Osf2/AML3 binding domain, and repeated half-sites for vitamin D3 and glucocorticoid receptors at -935 and -640. Short-term treatment with 1α,25(OH)2 VitD3 or dexamethasone increased promoter-driven luciferase activity ~2-fold. CpG methylation in the promoter region correlates with loss of osteoclastogenesis support capacity in stromal cells.\",\n      \"method\": \"Promoter cloning, transient transfection luciferase reporter assay, genomic Southern blot, CpG methylation analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assays with multiple stimuli, single lab, no in vivo validation of specific elements\",\n      \"pmids\": [\"10209265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TRANCE/OPGL undergoes ectodomain shedding to generate a soluble form. At least two distinct sheddase activities operate in different cell types, both distinct from TNF-alpha convertase (TACE/ADAM17). One sheddase is induced by the tyrosine phosphatase inhibitor pervanadate but not phorbol esters and is sensitive to TIMP-2 but not TIMP-1, consistent with a membrane-type matrix metalloprotease. A second sheddase is refractory to both stimuli.\",\n      \"method\": \"Biochemical characterization of cleavage site usage, pharmacological inhibition/activation with pervanadate and phorbol esters, TIMP-1 and TIMP-2 sensitivity assays in different cell types\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal pharmacological criteria in different cell lines, single lab, no direct protease identification\",\n      \"pmids\": [\"11278735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-γ produced by activated T cells inhibits RANKL-induced osteoclastogenesis by inducing rapid degradation of the RANK adapter protein TRAF6, resulting in strong inhibition of RANKL-induced NF-κB and JNK activation. Separately, RANKL induces IFN-β (but not IFN-α) gene expression in osteoclast precursor cells, and IFN-β strongly inhibits osteoclast differentiation by interfering with RANKL-induced expression of c-Fos. Both IFN-mediated mechanisms maintain bone resorption homeostasis in vivo.\",\n      \"method\": \"Genetic (IFN-KO mice, in vivo models), biochemical signaling assays (NF-κB, JNK activation), gene expression analysis, epistasis experiments\",\n      \"journal\": \"Arthritis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic KO, signaling biochemistry, in vivo validation), two distinct IFN mechanisms characterized\",\n      \"pmids\": [\"12110142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PTH upregulates RANKL mRNA in primary mouse bone marrow stromal osteoblasts with maximal sensitivity at late stages of osteoblast differentiation, while simultaneously inhibiting OPG gene expression at all stages. Changes in RANKL and OPG mRNA after PTH exposure are associated with increased osteoclastogenesis (increased TRACP+ cells in co-culture). PTH acts through at least protein kinase A pathway to regulate this balance.\",\n      \"method\": \"Quantitative real-time RT-PCR of RANKL and OPG mRNA at sequential differentiation stages, co-culture osteoclastogenesis assay with TRACP staining\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative gene expression plus functional co-culture readout, single lab, no direct mechanistic dissection of PTH receptor signaling to RANKL promoter\",\n      \"pmids\": [\"14969393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RANKL acts as a survival factor in mature osteoclasts by downregulating Fas expression and Fas-mediated apoptosis. During early osteoclastogenesis, RANKL upregulates Fas promoter activity via NF-κB binding sites. In differentiated mature osteoclasts, RANKL reduces Fas expression and protects from Fas-stimulated apoptosis. The regulation of Fas by RANKL is biphasic and NF-κB-dependent.\",\n      \"method\": \"Western blotting, RT-PCR, flow cytometry, nuclear staining, caspase-3 activity assay, luciferase reporter assay, EMSA with NF-κB site mutations\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in single lab, mutagenesis of NF-κB binding sites confirms mechanism\",\n      \"pmids\": [\"15619676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MafB negatively regulates RANKL-induced osteoclast differentiation. RANKL reduces MafB expression during osteoclastogenesis. Overexpression of MafB inhibits formation of TRAP+ multinuclear osteoclasts and attenuates RANKL-induced NFATc1 and OSCAR gene expression. MafB proteins directly interfere with the DNA-binding ability of c-Fos, Mitf, and NFATc1, inhibiting their transactivation of NFATc1 and OSCAR. RNAi knockdown of MafB enhances osteoclastogenesis.\",\n      \"method\": \"Overexpression and RNAi knockdown in bone marrow-derived monocyte/macrophage lineage cells, TRAP staining, gene expression analysis, DNA-binding interference assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both gain- and loss-of-function with mechanistic follow-up on transcription factor interference, single lab\",\n      \"pmids\": [\"17158225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RANKL expression in skeletal tissue is regulated by a distal enhancer element (RL-D2) located 23 kb upstream of the Tnfsf11 TSS. Deletion of RL-D2 blunts PTH-induced RANKL expression in vivo and in primary stromal cells ex vivo, and leads to decreased osteoclast numbers and increased bone mineral density (high bone mass phenotype). VDR and CREB bind to this enhancer in osteoblastic cells.\",\n      \"method\": \"ChIP-seq, ChIP-chip, genomic enhancer deletion in mice (RL-D2−/− knockout), ex vivo stromal cell cultures with PTH/forskolin/1,25(OH)2D3, bone phenotype analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — enhancer deletion in vivo with in vivo and ex vivo functional validation, ChIP-seq confirmation, clear skeletal phenotype\",\n      \"pmids\": [\"26332516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Human TNFSF11 expression in T cells is regulated by a distal enhancer region (-170 to -220 kb upstream of TSS) designated the human T cell control region (hTCCR), which is conserved with the mouse TCCR. c-FOS is recruited to the hTCCR. MEK1/2 signaling is required for RANKL induction in T cells. Enhancer segments mediate robust inducible reporter activity following TCR activation.\",\n      \"method\": \"ChIP-chip (H3/H4 acetylation), MEK1/2 inhibition with U0126, luciferase reporter assay with hTCCR segments, Jurkat cells and primary human T cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional reporter assays, MEK inhibition experiment, single lab\",\n      \"pmids\": [\"25211367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Genetic rescue of RANKL-null mice using a lymphocyte-specific promoter transgene restores osteoclasts and marrow spaces in long bone diaphyses but not in periosteum or jaws, demonstrating that local delivery of RANKL is required for many site-specific skeletal processes including tooth eruption, which was not rescued. The transgene had no effect on chondrodystrophy or growth plate defects, indicating distinct tissue requirements for RANKL.\",\n      \"method\": \"Transgenic rescue of RANKL knockout mice with lymphocyte-specific promoter, histological and TRAP staining of skeletal tissues\",\n      \"journal\": \"Connective tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via transgenic rescue with multiple tissue-specific readouts, single lab\",\n      \"pmids\": [\"12952207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RANKL inhibits angiogenesis: it potently inhibits basal and VEGF-induced microvessel formation in the rat aortic ring model, inhibits endothelial cell proliferation, and induces endothelial apoptosis. Signaling studies in HUVECs showed RANKL has no effect on ERK1/2 or Akt phosphorylation (in contrast to OPG which activates these pathways), indicating RANKL's anti-angiogenic effects operate through distinct mechanisms.\",\n      \"method\": \"Rat aortic ring angiogenesis assay, HUVEC proliferation and apoptosis assays, ERK1/2 and Akt phosphorylation signaling assays\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ex vivo and cell-based assays with multiple readouts, signaling characterized, single lab\",\n      \"pmids\": [\"19105036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXO1 is induced by RANKL and translocates to the nucleus in osteoclast precursors. Lineage-specific deletion of FOXO1 (LyzM.Cre+ FOXO1L/L) reduces RANKL-induced osteoclast formation and activity by ~50% in vivo and in vitro. FOXO1 mediates RANKL effects by regulating NFATc1 nuclear localization/expression and downstream osteoclast genes (DC-STAMP, ATP6vod2, cathepsin K, integrin αv). FOXO1 deletion also reduces M-CSF-induced RANK expression and osteoclast precursor migration.\",\n      \"method\": \"Conditional knockout mice (LyzM.Cre+ FOXO1L/L), siRNA knockdown in RAW264.7, in vitro osteoclastogenesis, in vivo bone phenotype, gene expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO plus siRNA with both in vivo and in vitro validation, single lab\",\n      \"pmids\": [\"25694609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-26a is upregulated by RANKL at late stages of osteoclastogenesis. miR-26a mimic suppresses osteoclast formation, actin-ring formation, and bone resorption by targeting connective tissue growth factor/CCN2 (CTGF), which promotes osteoclast formation via DC-STAMP upregulation. Overexpression of miR-26a inhibitor enhances RANKL-induced osteoclastogenesis. Recombinant CTGF rescues the inhibitory effect of miR-26a.\",\n      \"method\": \"miRNA mimic/inhibitor transfection in osteoclast precursors, TRAP staining, actin-ring assay, bone resorption assay, gene expression analysis, rescue with recombinant CTGF\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with rescue experiment confirming CTGF as target, single lab\",\n      \"pmids\": [\"25518928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RANKL-induced osteoclastogenesis involves an epigenetic reprogramming mechanism: RANKL induces formation of ~200 superenhancers (SEs) while suppressing ~148 SEs in human macrophages. RANKL-responsive SEs are enriched for BATF binding motifs; BATF1/3 depletion inhibits RANKL-induced osteoclast differentiation. RANKL also induces SE-associated enhancer RNAs (SE-eRNAs) at the NFATc1 locus; knockdown of SE-eRNA:NFATc1 diminishes NFATc1 expression and osteoclast differentiation. BET protein inhibition suppresses RANKL-responsive SEs and SE-eRNA:NFATc1 expression.\",\n      \"method\": \"ChIP-seq, ATAC-seq, nuclear RNA-seq, PRO-seq, BATF1/3 depletion, SE-eRNA knockdown, BET inhibitor treatment, human osteoclast differentiation assays\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal genome-wide and functional methods (ChIP-seq, ATAC-seq, KD with phenotypic rescue), single lab but highly rigorous\",\n      \"pmids\": [\"36513810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TNFα increases RANKL expression in osteoblastic cells via PGE2-dependent activation of NFATc1 and CREB. TNFα stimulates COX2, increasing PGE2 production, which activates NFAT transcriptional activity and drives NFATc1 and CREB binding to the RANKL promoter. Mutations in the NFAT-binding element or CRE-like element in the RANKL promoter suppress TNFα/PGE2-induced RANKL promoter activity. PGE2 receptor antagonists block TNFα-induced RANKL expression.\",\n      \"method\": \"Luciferase reporter assay with RANKL promoter mutants, ChIP, NFAT inhibitors, COX inhibitor, PGE2 receptor antagonists, in C2C12 and primary calvarial cells\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis, ChIP, pharmacological inhibition with multiple agents, single lab\",\n      \"pmids\": [\"28245593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RANKL induces beige adipocyte differentiation in preadipocytes. RANKL treatment of stromal vascular fraction (SVF) cells or 3T3-L1 preadipocytes induces multilocular morphology and increased expression of beige adipocyte marker genes. Infusion of RANKL increases respiratory rates in subcutaneous white adipose tissue and increases whole body oxygen consumption. Mature white adipocytes do not respond to RANKL-induced browning. OPG-/- mice show spontaneous sWAT browning.\",\n      \"method\": \"OPG knockout mouse model, RANKL infusion in vivo (indirect calorimetry), SVF cell differentiation assays, 3T3-L1 cell assays, histology, gene expression analysis\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo OPG-KO and RANKL infusion with in vitro cell differentiation assays, single lab\",\n      \"pmids\": [\"32315212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RANKL-stimulated osteoclasts undergo cell fission into daughter cells called osteomorphs rather than exclusively undergoing apoptosis. Inhibiting RANKL blocked this cellular recycling and caused osteomorph accumulation. Osteomorphs are transcriptionally distinct from osteoclasts and macrophages by single-cell RNA sequencing and express non-canonical osteoclast genes associated with bone phenotypes when deleted.\",\n      \"method\": \"Intravital imaging, single-cell RNA sequencing, RANKL inhibition experiments, genetic deletion of osteomorph genes in mice\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — intravital imaging plus scRNA-seq plus genetic validation, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"33636130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RANKL is highly expressed in Sertoli cells of the testis and signals through RANK expressed on germ cells, with OPG expressed in germ and peritubular cells. Mice with global or Sertoli-specific genetic suppression of Rankl have increased sperm counts and male fertility. OPG treatment increases wild-type mouse sperm counts. RANKL levels in seminal fluid are elevated and distinguish infertile from fertile men.\",\n      \"method\": \"Sertoli cell-specific and global Rankl knockout mice, OPG pharmacological treatment, seminal fluid RANKL measurement, immunohistochemistry for RANK/RANKL/OPG localization, human clinical intervention with denosumab\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic KO with functional fertility readout plus pharmacological OPG treatment, single lab\",\n      \"pmids\": [\"33893301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Under normoxia, RANKL stimulation induces ferroptosis in osteoclasts through an iron-starvation response (increased transferrin receptor 1, decreased ferritin) and activation of ferritinophagy via FTH-NCOA4 complex autophagosome degradation. This process is blocked under hypoxia, where HIF-1α inhibits autophagosome formation and autophagy flux, thereby reducing ferritinophagy. Aconitase activity reduction links RANKL stimulation to iron-starvation response.\",\n      \"method\": \"In vitro osteoclast differentiation under normoxia/hypoxia, iron homeostasis assays, autophagy flux measurement, HIF-1α inhibitor (2ME2) in vivo OVX model, FTH-NCOA4 interaction analysis\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular assays with in vivo validation, single lab, mechanism partially characterized\",\n      \"pmids\": [\"33895289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genetic inactivation of RANK in mammary epithelium markedly delayed onset and reduced incidence of Brca1;p53 mutation-driven mammary cancer. Long-term pharmacological RANKL inhibition abolished BRCA1 mutation-driven pre-neoplastic lesions in mice. RANK/RANKL blockade impaired proliferation and expansion of both murine Brca1;p53 mutant mammary stem cells and mammary progenitors from human BRCA1 mutation carriers.\",\n      \"method\": \"Conditional RANK knockout in mammary epithelium (two mouse models), pharmacological RANKL inhibition, mammary stem/progenitor cell proliferation assays, human BRCA1 carrier progenitor assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent mouse genetic models plus pharmacological blockade with human validation, multiple orthogonal methods\",\n      \"pmids\": [\"27241552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In situ hybridization revealed that RANKL (Tnfsf11) is expressed mainly by bone surface osteoprogenitor cells (co-expressing Mmp13, Limch1, Wif1) proximate to osteoclasts, while OPG is expressed mainly by osteocytes and bone-forming osteoblasts. OPG:Fc treatment increased RANKL mRNA in trabecular bone surface cells while decreasing OPG mRNA in both bone surface cells and osteocytes. PTH treatment had a similar but more pronounced effect. These findings suggest bone surface cells and osteocytes conjointly regulate osteoclastogenesis activation.\",\n      \"method\": \"In situ hybridization across multiple species and skeletal sites, OPG:Fc and PTH treatment of mice, scRNA-seq analysis of murine bone marrow stromal cells\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ISH localization with functional pharmacological interventions in vivo, supported by scRNA-seq, single lab\",\n      \"pmids\": [\"39424806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RANKL and RANK are present as functional components in extracellular vesicles (EVs). RANK in EVs from osteoclasts can stimulate a RANKL reverse signaling pathway in osteoblasts that promotes bone formation, serving to couple bone resorption with bone formation.\",\n      \"method\": \"Extracellular vesicle isolation, functional assays of RANK-containing EVs on osteoblast bone formation\",\n      \"journal\": \"Extracellular vesicles and circulating nucleic acids\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review article summarizing EV findings; limited primary experimental detail available in this abstract\",\n      \"pmids\": [\"33982033\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RANKL (TNFSF11) is a TNF-family membrane-bound and soluble cytokine expressed by osteoblasts, osteocytes, and other cells that acts as the essential ligand for the receptor RANK on osteoclast precursors and mature osteoclasts, driving osteoclast differentiation, activation (actin ring formation), and survival by suppressing Fas-mediated apoptosis via NF-κB, while its activity is antagonized by the soluble decoy receptor OPG; RANKL expression is transcriptionally controlled by distal genomic enhancers (RL-D2, RL-D5, hTCCR) responsive to PTH, 1,25(OH)2D3, and TCR activation via VDR, CREB, c-Fos, and NFATc1 binding, and is epigenetically reprogrammed during osteoclastogenesis through superenhancer remodeling involving BATF and SE-eRNAs; RANKL also regulates lymph-node organogenesis, lymphocyte development, mammary gland lactational development, thermoregulation via CNS COX2-PGE2/EP3R signaling, male fertility via Sertoli cell-germ cell RANK signaling, beige adipocyte differentiation, and BRCA1-driven mammary tumorigenesis by controlling progenitor cell expansion, and undergoes ectodomain shedding by at least two distinct metalloprotease activities to generate its soluble form.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFSF11 (RANKL) is the essential, membrane-bound and soluble TNF-family cytokine that licenses osteoclast formation and broader developmental programs, established genetically by the complete absence of osteoclasts, lymph nodes, and normal lymphocyte differentiation in knockout mice [#0]. Expressed as a membrane-associated cytokine on osteoblasts and stromal cells, RANKL signals through cell-to-cell contact to RANK on hematopoietic osteoclast precursors, driving their differentiation in the presence of M-CSF; soluble RANKL generated by ectodomain shedding can act at a distance, and the decoy receptor OPG blocks the RANKL-RANK interaction [#2, #4]. In situ analysis localizes RANKL to bone-surface osteoprogenitor cells adjacent to osteoclasts while OPG is enriched in osteocytes and bone-forming osteoblasts, defining a spatially partitioned regulatory circuit [#22]. Beyond differentiation, RANKL directly activates mature osteoclasts—rapidly inducing actin-ring formation and bone-surface erosion through RANK [#1]—and acts as a survival factor by suppressing Fas-mediated apoptosis in an NF-κB-dependent, biphasic manner [#7]. Downstream of RANK, RANKL drives a transcriptional cascade centered on NFATc1 and c-Fos, modulated positively by FOXO1 [#13] and restrained by MafB, which interferes with c-Fos, Mitf, and NFATc1 DNA binding [#8]; this program is amplified through epigenetic reprogramming, with RANKL inducing BATF-dependent superenhancers and an SE-eRNA at the NFATc1 locus [#15]. RANKL transcription itself is controlled by distal enhancers responsive to PTH and 1,25(OH)2D3 via VDR and CREB in osteoblasts (RL-D2) [#9] and to TCR/MEK signaling via c-FOS in T cells (hTCCR) [#10], and by TNFα through PGE2-driven NFATc1/CREB binding to the promoter [#16]. Osteoclastogenesis is counter-regulated by IFN-β (which suppresses c-Fos) and by T-cell-derived IFN-γ (which degrades TRAF6) [#5]. RANKL also operates well beyond bone, governing beige adipocyte differentiation and thermogenesis [#17], Sertoli-cell-to-germ-cell signaling that restrains male fertility [#19], and BRCA1/p53-driven mammary tumorigenesis through expansion of mammary stem and progenitor cells [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing whether RANKL is genuinely required for osteoclast formation in vivo answered whether bone resorption depends on a single dedicated ligand and revealed its developmental breadth.\",\n      \"evidence\": \"Gene knockout mouse with skeletal, immunological, and lymph-node phenotyping\",\n      \"pmids\": [\"9950424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve the receptor or signaling mechanism\", \"Does not distinguish membrane-bound versus soluble ligand requirements\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defining how RANKL is presented to precursors and how it engages mature cells answered whether it acts via contact-dependent membrane signaling and direct activation through RANK.\",\n      \"evidence\": \"Osteoblast/precursor co-culture, spot-culture distinguishing membrane vs soluble forms, primary osteoclast bone-slice assays with anti-RANK and OPG blockade\",\n      \"pmids\": [\"10080918\", \"10976996\", \"10225954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the intracellular signaling adapters\", \"Does not define the sheddase generating soluble RANKL\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Characterizing ectodomain shedding answered how the soluble RANKL form is produced, revealing at least two distinct metalloprotease activities separable from TACE/ADAM17.\",\n      \"evidence\": \"Pharmacological shedding assays with pervanadate/phorbol esters and TIMP-1/TIMP-2 sensitivity across cell types\",\n      \"pmids\": [\"11278735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No protease molecularly identified\", \"Physiological contribution of soluble vs membrane RANKL in vivo unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping immune counter-regulation answered how T-cell signals brake osteoclastogenesis, identifying TRAF6 degradation by IFN-γ and c-Fos suppression by RANKL-induced IFN-β.\",\n      \"evidence\": \"IFN-knockout mice, NF-κB/JNK signaling biochemistry, gene expression and epistasis\",\n      \"pmids\": [\"12110142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not quantify relative contribution of the two IFN arms in disease\", \"Mechanism of RANKL-induced IFN-β induction not fully dissected\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Dissecting promoter and rescue requirements answered how RANKL transcription responds to vitamin D/glucocorticoids and whether local versus systemic delivery dictates site-specific skeletal function.\",\n      \"evidence\": \"Promoter luciferase reporters with CpG methylation analysis; lymphocyte-promoter transgenic rescue of RANKL-null mice\",\n      \"pmids\": [\"10209265\", \"12952207\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter elements not validated in vivo at endogenous locus\", \"Does not explain tooth-eruption and growth-plate non-rescue mechanistically\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolving the survival role answered whether RANKL controls osteoclast lifespan, showing biphasic NF-κB-dependent regulation of Fas.\",\n      \"evidence\": \"Reporter assays, EMSA with NF-κB site mutants, caspase-3 and apoptosis assays in osteoclasts\",\n      \"pmids\": [\"15619676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Switch governing the early-up/late-down biphasic response not defined\", \"In vivo relevance to bone turnover not established here\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying MafB answered how the osteoclast transcriptional program is restrained, placing a brake on c-Fos/Mitf/NFATc1 DNA binding downstream of RANKL.\",\n      \"evidence\": \"Overexpression/RNAi in monocyte lineage cells, TRAP staining, DNA-binding interference assays\",\n      \"pmids\": [\"17158225\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream control of MafB downregulation by RANKL unresolved\", \"Structural basis of transcription-factor interference not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Testing vascular effects answered whether RANKL acts on endothelium, showing it inhibits angiogenesis through mechanisms distinct from OPG-driven ERK/Akt activation.\",\n      \"evidence\": \"Rat aortic ring assay, HUVEC proliferation/apoptosis, ERK1/2 and Akt phosphorylation assays\",\n      \"pmids\": [\"19105036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor and signaling pathway mediating anti-angiogenic effect unidentified\", \"In vivo angiogenesis relevance not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Adding a microRNA layer answered how RANKL fine-tunes late osteoclastogenesis, with miR-26a targeting CTGF to limit DC-STAMP-driven fusion.\",\n      \"evidence\": \"miRNA mimic/inhibitor transfection, TRAP/actin-ring/resorption assays, recombinant CTGF rescue\",\n      \"pmids\": [\"25518928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo skeletal role of the miR-26a/CTGF axis untested\", \"How RANKL induces miR-26a not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping enhancers in osteoblasts and T cells answered how RANKL transcription is wired to hormonal and immune cues, defining RL-D2 (VDR/CREB, PTH-responsive) and the hTCCR (c-FOS, MEK/TCR-responsive), and FOXO1 as an intracellular RANKL effector.\",\n      \"evidence\": \"ChIP-seq/ChIP-chip, in vivo enhancer deletion (RL-D2−/−), hTCCR reporter and MEK inhibition; FOXO1 conditional KO and siRNA with osteoclast assays\",\n      \"pmids\": [\"26332516\", \"25211367\", \"25694609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk between osteoblast and T-cell enhancers not addressed\", \"FOXO1 mechanism of NFATc1 regulation only partly defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genome-wide epigenetic profiling answered how RANKL reprograms the osteoclast genome, identifying BATF-dependent superenhancers and an NFATc1 SE-eRNA as essential drivers.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, PRO-seq, BATF1/3 depletion, SE-eRNA knockdown, BET inhibition in human osteoclasts\",\n      \"pmids\": [\"36513810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling linking RANK to BATF recruitment unresolved\", \"Mechanism of SE-eRNA action on NFATc1 not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Probing the mammary axis answered whether RANK/RANKL drives BRCA1-mutant tumorigenesis, showing it expands cancer-prone stem and progenitor cells.\",\n      \"evidence\": \"Conditional mammary RANK KO (two models), pharmacological RANKL inhibition, murine and human BRCA1-carrier progenitor assays\",\n      \"pmids\": [\"27241552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of RANK in progenitor expansion not identified\", \"Does not establish RANKL source within the mammary niche\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Testing adipose effects answered whether RANKL influences metabolism, showing it drives beige adipocyte differentiation and thermogenesis in precursors but not mature white adipocytes.\",\n      \"evidence\": \"OPG-KO mice, in vivo RANKL infusion with indirect calorimetry, SVF and 3T3-L1 differentiation assays\",\n      \"pmids\": [\"32315212\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/signaling pathway in preadipocytes not defined\", \"Whether RANKL acts cell-autonomously on precursors unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Imaging osteoclast fate answered whether resorbing cells simply die, revealing RANKL-dependent fission into transcriptionally distinct osteomorphs that recycle.\",\n      \"evidence\": \"Intravital imaging, single-cell RNA-seq, RANKL inhibition, genetic deletion of osteomorph genes\",\n      \"pmids\": [\"33636130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of fission versus apoptosis not defined\", \"Functional contribution of osteomorph recycling to bone homeostasis incompletely quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Examining testis and cell-death pathways answered additional non-skeletal and metabolic roles: Sertoli-cell RANKL restrains male fertility via germ-cell RANK, and RANKL induces ferroptosis through ferritinophagy in normoxic osteoclasts.\",\n      \"evidence\": \"Sertoli-specific/global Rankl KO, OPG and denosumab treatment, seminal RANKL measurement; iron-homeostasis and autophagy-flux assays with HIF-1α inhibition in OVX model\",\n      \"pmids\": [\"33893301\", \"33895289\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Germ-cell signaling downstream of RANK in fertility not mapped\", \"In vivo significance of RANKL-induced ferroptosis under physiological oxygen tension unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Proposing EV-borne reverse signaling addressed how resorption couples to formation, suggesting osteoclast EV RANK triggers RANKL reverse signaling in osteoblasts.\",\n      \"evidence\": \"EV isolation and functional assays on osteoblast bone formation (review summary)\",\n      \"pmids\": [\"33982033\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Review-level summary lacking primary mechanistic detail\", \"RANKL reverse-signaling pathway in osteoblasts not molecularly defined\", \"In vivo contribution to coupling unestablished\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Spatial localization answered which cells supply RANKL versus OPG, defining a division of labor between bone-surface osteoprogenitors and osteocytes in regulating osteoclastogenesis.\",\n      \"evidence\": \"In situ hybridization across species/sites, OPG:Fc and PTH treatment, scRNA-seq of bone marrow stroma\",\n      \"pmids\": [\"39424806\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coordinating the two cell populations not defined\", \"Does not establish causal contribution of each source in vivo\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the RANKL sheddases, the receptor mediating its non-skeletal effects (angiogenesis, adipose browning), and the molecular basis of RANKL reverse signaling remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Sheddase enzymes not molecularly identified\", \"Receptor for anti-angiogenic and beige-adipocyte effects unknown\", \"Reverse-signaling pathway in osteoblasts uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0006954\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TNFRSF11A\", \"TNFRSF11B\"]\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}